APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors), Immunomodulators

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [9]

Active Indication

Myasthenia GravisRheumatoid ArthritisSystemic Lupus Erythematosus+ [16]

Inactive Indication-

Originator Organization

RemeGen Co., Ltd.

Active Organization

RemeGen Co., Ltd.

Vor Biopharma, Inc.

Inactive Organization-

License Organization

Vor Biopharma, Inc.

RemeGen Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

China (09 Mar 2021),

Systemic Lupus Erythematosus

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (Japan), Fast Track (United States)

Structure/Sequence

Sequence Code 616721115

Source: *****

102

Clinical Trials associated with Telitacicept

ChiCTR2600120420

/ Not yet recruitingNot ApplicableIIT

A randomized controlled trial of different doses of tegiletidine versus sufentanil for postoperative patient-controlled intravenous analgesia (PCIA) in patients with gynecological malignancies undergoing laparoscopic surgery

Start Date18 Mar 2026

Sponsor / Collaborator-

NCT07298928

/ Not yet recruitingNot ApplicableIIT

The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health

Under conventional treatment regimens, pediatric ocular myasthenia gravis (OMG) is prone to relapse and is associated with corticosteroid-related adverse effects, indicating an unmet clinical need. In May 2025, the targeted B-cell biologic agent Telitacicept was approved for use in adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (GMG) and subsequently initiated in national multicenter clinical trials for adult OMG. Our center published a retrospective study in the Chinese Journal of Evidence-Based Pediatrics in August 2025, which was the first report both domestically and internationally on the efficacy and safety of Telitacicept in four pediatric OMG patients. This study plans to conduct a prospective, multicenter, open-label, single-arm clinical trial aimed at evaluating the effectiveness and safety of Telitacicept in pediatric OMG.

Start Date10 Mar 2026

Sponsor / Collaborator

The Children's Hospital of Zhejiang University School of Medicine

ChiCTR2600118445

/ Not yet recruitingPhase 4IIT

Exploratory Study Protocol on the Efficacy and Safety of Telitacicept for Injection in Patients with Primary Sjögren's Syndrome Complicated by Hematologic Involvement

Start Date01 Mar 2026

Sponsor / Collaborator-

100 Clinical Results associated with Telitacicept

100 Translational Medicine associated with Telitacicept

100 Patents (Medical) associated with Telitacicept

183

Literatures (Medical) associated with Telitacicept

01 Jun 2026·CURRENT OPINION IN IMMUNOLOGY

Clinical trials and new therapies in Sjögren’s disease

Review

Author: Grader-Beck, Thomas ; Salas, Antonio ; Patel, Vishal

Despite major advances in understanding Sjögren's disease (SjD), no approved disease-modifying therapies have been approved. Management remains largely symptomatic with the use of off-label immunomodulators for systemic features. This gap highlights the substantial unmet need for targeted treatment. Encouragingly, the therapeutic landscape is shifting. Several phase 2 trials have shown meaningful efficacy signals, and for the first time, phase 3 programs with ianalumab and telitacicept have demonstrated positive outcomes, particularly when systemic activity is assessed using the EULAR Sjögren's Syndrome Disease Activity Index. These successes reflect both the maturation of the therapeutic pipeline and important refinements in trial design. Insights from earlier negative studies have underscored the importance of enrolling patients with active disease, incorporating biomarker-defined subgroups, and development of composite endpoints that integrate systemic, symptomatic, and functional domains. Together, these developments suggest that SjD may finally be approaching an era of effective, disease-modifying therapy.

01 Apr 2026·CLINICAL IMMUNOLOGY

The efficacy of rituximab plus telitacicept in neuropsychiatric systemic lupus erythematosus: A retrospective study

Article

Author: He, Jiawei ; Jiang, Lijuan ; Mei, Chunli ; Zhao, Liqin

OBJECTIVE:

Neuropsychiatric systemic lupus erythematosus (NPSLE) presents significant management challenges and high mortality. While rituximab (RTX) is used via B cell depletion, telitacicept's efficacy remains unclear. This study retrospectively evaluated telitacicept, alone or after RTX, in NPSLE treatment.

METHODS:

We analyzed 38 NPSLE patients from two Chinese centers, divided into conventional therapy (n = 11), telitacicept therapy (n = 15), and RTX followed by telitacicept (n = 12). Outcomes included event-free survival (EFS), self-care and modified Rankin Scale (mRS) scores, SLEDAI-2 K, and SLEDAI-NP.

RESULTS:

Telitacicept and RTX plus telitacicept groups showed effective B cell depletion and improved EFS, self-care, and mRS scores versus conventional therapy. Glucocorticoid tapering was most rapid with RTX plus telitacicept. Infections were manageable in telitacicept-based groups, while conventional therapy had higher severe event rates.

CONCLUSIONS:

Telitacicept is promising for NPSLE, both as monotherapy and following RTX induction. Confirmation of its efficacy and safety in this study, however, requires further prospective investigation.

01 Mar 2026·CLINICAL RHEUMATOLOGY

Telitacicept for childhood HSPN: A prospective self-controlled study

Article

Author: Wang, Mo ; Zhang, Hanhan ; Chen, Chenchen ; Zhang, Junjun ; Jiang, Caixia ; Ding, Ying ; Song, Dan ; Song, Ke ; Song, Chundong ; Guo, Xiaoxiao

OBJECTIVES:

To investigate the efficacy and safety of Telitacicept (RC18) in children with Henoch-Schönlein Purpura Nephritis (HSPN).

METHODS:

A prospective self-controlled study enrolled HSPN children from the First Affiliated Hospital of Henan University of Chinese Medicine from December 2023 to January 2025. Clinical and laboratory indices and adverse reactions were recorded during 1-4 months of follow-up. Primary study endpoint was 24 h UTP, and the secondary study endpoints included urinary RBC count, renal function (BUN, UA, Scr, eGFR) and safety. Exploratory analysis included dynamic changes in lymphocytes, BAFF, APRIL and Gd-IgA1.

RESULTS:

Twenty-one patients were enrolled. After Telitacicept treatment, the 24 h UTP response rate was 100%, and urine RBC response rate was 66.7%. Renal function remained stable. Compared with baseline, 24 h UTP values and the reduction rate were significantly decreased at 4 months (P < 0.01), and urinary RBC count was significantly decreased at 3 months (P < 0.01). Exploratory analyses showed that the percentage of CD19 + decreased, while there was no decrease in CD3 + , CD3 + CD4 + , and CD3 + CD8 + cells. Meanwhile, the Gd-IgA1 level trended downward. Safety assessment demonstrated no serious adverse reactions, with abnormalities observed in biochemical parameters (ALT: 4.8%; UA: 19.0%) and injection site reactions (14.3%).

CONCLUSION:

RC18 effectively reduces urine protein and RBC in HSPN children, with good clinical effects and safety. Key Points • Efficacy and safety study of Telitacicept in the treatment of children with HSPN. • Preliminary exploration on the mechanism of Telitacicept in the treatment of children with HSPN.

News (Medical) associated with Telitacicept

11 Mar 2026

·allsci.com

Vertex hopeful on first-mover status for BAFF+APRIL povetacicept after Phase III data

Vertex Pharmaceuticals announced positive results from a pre-specified Week 36 interim analysis of the RAINIER Phase III trial evaluating povetacicept in adults with IgA nephropathy, meeting the primary endpoint and all secondary endpoints. IgAN is the most common form of primary glomerulonephritis, affecting an estimated 330,000 people in the US and Europe, with up to 72% of adult patients progressing to end-stage renal disease or death within two decades of diagnosis. The data position Vertex’s povetacicept as a potential first dual BAFF+APRIL inhibitor to reach registration in this disease. RAINIER is a global, randomized, double-blind, placebo-controlled Phase III trial evaluating povetacicept 80 mg administered subcutaneously every four weeks versus placebo on top of standard of care. A total of 605 patients were randomized: 557 in the main cohort and 48 in an exploratory cohort with lower baseline eGFR (20 to <30 mL/min/1.73m²). The interim analysis population comprised 199 patients from the main cohort (131 povetacicept, 68 placebo). Background supportive care rates were high, with 97.8% of patients on ACEi/ARBs and 67.7% on SGLT2 inhibitors, a proportion the company described as the highest in any contemporary IgAN trial. For the primary endpoint, povetacicept-treated patients achieved a 52.0% reduction from baseline in 24-hour urine protein to creatinine ratio (UPCR), compared with a 4.3% reduction in the placebo arm, yielding a 49.8% reduction versus placebo (P<0.0001). The povetacicept Phase III results on secondary endpoints were similarly consistent: serum galactose-deficient IgA1 (Gd-IgA1) fell 77.4% from baseline versus a 9.1% increase with placebo (79.3% reduction versus placebo; P<0.0001), and 85.1% of povetacicept-treated patients with baseline hematuria achieved resolution compared with 23.4% on placebo (P<0.0001). An exploratory endpoint showed 42.2% of povetacicept patients achieved UPCR below 0.5 g/g versus 6.2% on placebo. Povetacicept was generally well tolerated. Adverse event rates were similar between arms (75.0% versus 78.4% for placebo). Injection site reactions occurred in 14.5% of the povetacicept group, all mild or moderate. There were no deaths, no drug-related serious adverse events, and no opportunistic infections. Treatment discontinuations were lower in the povetacicept arm (3.8%) than placebo (8.8%). The US FDA has granted rolling review of the Biologics License Application for povetacicept in IgAN, and Vertex stated it will complete the full BLA submission by the end of March, using a priority review voucher to shorten the review timeline from ten to six months. Reshma Kewalramani, Vertex’s CEO, said the data “bring us one step closer to realizing povetacicept’s pipeline-in-a-product promise”. The RAINIER trial continues blinded toward a final two-year analysis with a primary endpoint of total eGFR slope through Week 104. Vertex is also advancing povetacicept in the Phase II/III OLYMPUS trial in primary membranous nephropathy and plans to initiate a Phase II trial in generalized myasthenia gravis in H1 2026. Povetacicept is an engineered TACI-Fc fusion protein that simultaneously inhibits BAFF and APRIL, two cytokines that drive B cell activation, differentiation, and survival. In IgAN, pathogenic B cells produce Gd-IgA1, which forms immune complexes that deposit in the kidney’s glomerular mesangium, triggering inflammation and fibrosis. By neutralizing both cytokines, povetacicept aims to suppress the upstream immunological drivers of disease rather than managing downstream consequences alone. IgAN treatment has historically relied on supportive care with renin-angiotensin system blockade. Recent approvals have begun to change the landscape: the US FDA approved Travere Therapeutics’ sparsentan (Filspari), a dual endothelin and angiotensin receptor antagonist, under accelerated approval in 2023 for IgAN with proteinuria. Calliditas Therapeutics’ budesonide delayed-release (Tarpeyo) received accelerated approval in 2021 as a targeted-release corticosteroid. Neither of these agents shares povetacicept’s mechanism. Key competitors targeting BAFF and/or APRIL in IgAN include: Vera Therapeutics’ atacicept, a TACI-Ig fusion protein and dual BAFF/APRIL inhibitor in the Phase III ORIGIN trial for IgAN, which represents the most direct mechanistic competitor to povetacicept. Otsuka/ Visterra, Inc.’s sibeprenlimab (VIS649), an anti-APRIL monoclonal antibody that reported Phase III data in IgAN and targets only one of the two cytokines inhibited by povetacicept. China-based RemeGen’s telitacicept, another dual BAFF/APRIL TACI-Fc fusion protein approved in China for systemic lupus erythematosus and in Phase II development for additional autoimmune indications, though its IgAN program is less advanced. Vor Bio secured a license to telitacicept’s ex-China rights in a June 2025 deal. GSK’s belimumab, a BAFF-only monoclonal antibody approved for SLE and lupus nephritis, is not in active IgAN development. The povetacicept proteinuria reduction of nearly 50% over placebo at 36 weeks, combined with the depth of Gd-IgA1 suppression and hematuria resolution, will be measured against atacicept and sibeprenlimab data as physicians and regulators assess the emerging class. Whether these surrogate endpoint improvements translate into durable preservation of kidney function will depend on the two-year eGFR data still to come from RAINIER.

Phase 3Clinical ResultDrug ApprovalPhase 2Priority Review

12 Jan 2026

·www.fiercebiotech.com

AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle

As far back as August 2025, AbbVie was suggesting it wanted to secure a spot in the PD1xVEGF race.\n AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. Now, the Big Pharma has paid $650 million to make its ambitions in this arena a reality.The company is handing the upfront cash to RemeGen for the ex-China rights to a bispecific called RC148. Shandong, China-based RemeGen will also be in line for up to $4.95 billion in development, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on net sales should AbbVie manage to get RC148 approved.RemeGen has taken RC148 into phase 2 development in China as a treatment for advanced solid tumors. Early clinical data have “shown initial favorable antitumor activity” in combination with an antibody-drug conjugate, AbbVie explained in a Jan. 12 release.The race to develop oncology bispecifics has been heating up in recent months, with Pfizer offering investors a first look last November at its strategy to dethrone Keytruda and establish its newly acquired PD-1xVEGF drug as a new cornerstone of cancer immunotherapy.Meanwhile, Summit Therapeutics/Akeso’s first-in-class PD-1xVEGF bispecific ivonescimab has already reported phase 3 data in non-small cell lung cancer—albeit from a China-only study. Back in September, BioNTech and Bristol Myers Squibb revealed the first global data for their PD-L1xVEGF bispecific in small cell lung cancer.As far back as August 2025, AbbVie was suggesting it wanted to secure a spot in this PD1xVEGF race. On an earnings call that month, the pharma’s chief scientific officer, Roopal Thakkar, M.D., said the company was “monitoring that class.”“There are several assets that are revealing data over time,” Thakkar told analysts in response to a question. “But it is something that we\'re interested in and looking at.”The CSO noted on that call last year that AbbVie was particularly interested in how a bispecific could partner with one of the pharma’s in-house ADCs, and this appears to be the case with RC148.In this morning’s release, AbbVie said RemeGen’s asset “may offer new opportunities to explore combination regimens with AbbVie\'s ADCs such as investigational telisotuzumab adizutecan (Temab-A), across multiple solid tumors with high unmet need including non-small cell lung cancer and colorectal cancer.”“Our partnership with RemeGen reflects AbbVie\'s commitment to not only advance novel oncology treatments, but also to build strong collaborations with biopharmaceutical innovators globally as an increasingly important source of scientific and clinical progress,” Daejin Abidoye, M.D., AbbVie’s head of oncology, solid tumor and hematology, said in a statement.“By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors,” Abidoye added. RemeGen markets telitacicept, a dual inhibitor of B lymphocyte stimulator and A proliferation-inducing ligand A, in China for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis. That drug is at the center of an ex-China licensing agreement with Massachusetts biotech Vor Bio that could be worth more than $4 billion.The company’s CEO Jianmin Fang, Ph.D., said today’s deal “underscores RemeGen\'s commitment to bringing cutting-edge therapies to patients worldwide.”“Working with AbbVie, we look forward to maximizing RC148\'s clinical and commercial potential in China and globally,” the CEO added.

License out/inADCImmunotherapyPhase 2Phase 3

12 Jan 2026

·news.abbvie.com

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors. PD-1/VEGF-targeted bispecific antibodies represent a new class of cancer therapies that aim to help the immune system fight tumors more effectively and potentially overcome tumor resistance mechanisms by blocking both PD-1 and VEGF simultaneously. Additionally, given their potential to modulate both immune suppression and foster a favorable tumor microenvironment for antibody-drug conjugate (ADC) activity, PD-1/VEGF bispecific antibodies are also being explored in combination with ADCs. In early clinical studies, RC148 has shown initial favorable antitumor activity in combination with an ADC. RC148 further strengthens AbbVie's diverse oncology portfolio. In particular, it may offer new opportunities to explore combination regimens with AbbVie's ADCs such as investigational telisotuzumab adizutecan (Temab-A), across multiple solid tumors with high unmet need including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). "Our partnership with RemeGen reflects AbbVie's commitment to not only advance novel oncology treatments, but also to build strong collaborations with biopharmaceutical innovators globally as an increasingly important source of scientific and clinical progress," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology at AbbVie. "By combining the immune checkpoint inhibition and anti-angiogenic activity of RC148 together with the targeted cytotoxic activity of ADCs, we have the potential to identify meaningful options for patients across a range of solid tumors." "This collaboration is a significant milestone for RemeGen, highlighting the innovative potential of RC148 in addressing critical unmet medical needs in cancer treatment," said Dr. Jianmin Fang, chief executive officer of RemeGen. "The deal further underscores RemeGen's commitment to bringing cutting-edge therapies to patients worldwide. Working with AbbVie, we look forward to maximizing RC148's clinical and commercial potential in China and globally." Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 outside of the Greater China territory. RemeGen will receive an upfront payment of USD $650 million and is eligible to receive up to USD $4.95 billion in aggregate development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales outside the Greater China territory. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube. About AbbVie in Oncology AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology. About RemeGen RemeGen Co., Ltd. is a leading innovative biopharmaceutical company in China focused on the discovery, development, manufacturing and commercialization of proprietary biologics. The company is dual-listed on the Hong Kong Stock Exchange and the STAR Market of the Shanghai Stock Exchange. RemeGen has built a highly differentiated pipeline across autoimmune, oncology and ophthalmology, with a proven ability to rapidly translate innovative science into clinically and commercially meaningful medicines. Its two flagship products, telitacicept and disitamab vedotin, have received approvals for a total of six indications in China, underscoring RemeGen's strong capabilities in first-/best-in-class biologics discovery, efficient clinical execution and successful commercialization. Additional information is available on the company's website at https://www.remegen.com/ Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. AbbVie contacts: Media: Sourojit (Jit) Bhowmick, Ph.D. jit.bhowmick@abbvie.com Investors: Liz Shea liz.shea@abbvie.com SOURCE AbbVie

License out/inImmunotherapyADC

100 Deals associated with Telitacicept

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L04AA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myasthenia Gravis	China	RemeGen Co., Ltd.	20 May 2025
Rheumatoid Arthritis	China	RemeGen Co., Ltd.	16 Jul 2024
Systemic Lupus Erythematosus	China	RemeGen Co., Ltd.	09 Mar 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, IGA	NDA/BLA	China	RemeGen Co., Ltd.	14 Oct 2025
Sjogren's Syndrome	NDA/BLA	China	RemeGen Co., Ltd.	09 Sep 2025
Idiopathic Inflammatory Myopathies	Phase 3	China	RemeGen Co., Ltd.	24 Feb 2026
Interstitial lung disease due to connective tissue disease	Phase 3	China	RemeGen Co., Ltd.	24 Feb 2026
Myasthenia Gravis, Ocular	Phase 3	China	RemeGen Co., Ltd.	13 Jan 2026
Muscular Diseases	Phase 3	United States	Vor Biopharma, Inc.	25 Feb 2025
Muscular Diseases	Phase 3	China	Vor Biopharma, Inc.	25 Feb 2025
Muscular Diseases	Phase 3	Japan	Vor Biopharma, Inc.	25 Feb 2025
Muscular Diseases	Phase 3	Argentina	Vor Biopharma, Inc.	25 Feb 2025
Muscular Diseases	Phase 3	Australia	Vor Biopharma, Inc.	25 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05673993 (ACR2025)	Phase 3	Sjogren's Syndrome	381	Telitacicept 160 mg	jzmwwxsmgo(qdypbjegta) = euochhwwzg rnehhfbibz (eyqabuwbgz ) View more	Positive	24 Oct 2025
				Telitacicept 80 mg	jzmwwxsmgo(qdypbjegta) = tkvjgyfllg rnehhfbibz (eyqabuwbgz ) View more
NCT04082416 (GlobeNewswire \| N Engl J Med \| Pubmed) Manual	Phase 3	Systemic Lupus Erythematosus	335	Telitacicept 160 mgTelitacicept 160 mg + standard therapy	wzujwenvhr(fjelxhqpqq) = cwewkhqyqt msihoneggk (egkehesbzr ) Met View more	Positive	15 Oct 2025
				Placebo + standard therapy	wzujwenvhr(fjelxhqpqq) = hrcpkoslyv msihoneggk (egkehesbzr ) Met View more
NCT05673993 (GlobeNewswire \| ACR2025) Manual	Phase 3	Primary Sjögren's syndrome	381	Telitacicept 160mg	corbkxfuqi(algrncomai) = naoqbyhvzc sfocfpfccw (bidodofhtq ) Met View more	Positive	14 Oct 2025
				Telitacicept 80mg	corbkxfuqi(algrncomai) = lnradkyirz sfocfpfccw (bidodofhtq ) Met View more
NCT05799287 (Corporate Publications) Manual	Phase 3	Glomerulonephritis, IGA	318	泰它西普	kfkbhzydef(egsalrjcmb): Difference (%) = 55, P-Value = <0.0001 Met	Positive	27 Aug 2025
				Placebo
PRNewswire Manual	Phase 3	Primary Sjögren's syndrome	-	Telitacicept	rrixmkxery(klnyzzcpkr) = The clinical results demonstrated that Telitacicept sustainably and effectively improved the clinical symptoms of Sjögren's syndrome patients, while showing favorable safety profile. mjgvoaggtv (vrtsmfmidf ) Met	Positive	13 Aug 2025
				Placebo
GlobeNewswire Manual	Phase 3	Primary Sjögren's syndrome	-	Telitacicept	pimjljpafk(sfiyhpizor) = reduction ntojlubabz (fssheoaiqh ) Met	Positive	13 Aug 2025
Pubmed \| Pediatr Nephrol	Not Applicable	Purpura, Schoenlein-Henoch	7	Telitacicept (Refractory childhood IgA vasculitis nephritis)	rmozpsruyn(trqnzdvvwg) = hvbrorsrqo svlqihbodf (azkjgsnrsr )	Positive	01 Aug 2025
EULAR2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic \| Systemic Lupus Erythematosus	22	Telitacicept 160mg/week	zszodinvxn(cubjyvrrvi) = The main adverse reactions observed in this study were infections, with 1 patient experiencing pulmonary infection and 1 patient developing herpes zoster yrpvvvssgb (chvsgdewhv )	Positive	11 Jun 2025
NCT05737160 (PipelineReview) Manual	Phase 3	Myasthenia Gravis	114	Telitacicept 240 mg	hojmdcoqnv(vqfaqxcyzc) = xgfgzmyoew jpcbanwmzj (juyuxrqxgg ) View more	Positive	08 Apr 2025
				Placebo	hojmdcoqnv(vqfaqxcyzc) = gamyxnmcga jpcbanwmzj (juyuxrqxgg ) View more
NCT06456580 (RemeMG, AAN2025) Manual	Phase 3	Myasthenia Gravis	114	Telitacicept 240 mg	dfkdpxremz(rvebkqtymg) = fwxggwygtu urirzqaxpx (oohejjphit ) View more	Positive	05 Apr 2025
				Placebo	dfkdpxremz(rvebkqtymg) = bcfstbhemc urirzqaxpx (oohejjphit ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis